SheltonSNelsonJDMcCrackenGH. In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, RO 13-9904 and other cephalosporins. Antimicrob Agents Chemother1980; 18: 476–9.
2.
MasonEOKaplanSLAndersonDCHindsDBFeiginRD. In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillin. Antimicrob Agents Chemother1980; 17: 470–3.
3.
SchaadUBMcCrackenGHThrelkeldNThomasML. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr1981; 98: 129–36.
4.
KaplanSLMasonEOGarciaH. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis. J Pediatr1981; 98: 152–7.
5.
ThirumoorthiMCBuckleyJAAravindMKKauffmanREDajaniAS. Diffusion of moxalactam into the cerebrospinal fluid in children with bacterial meningitis. J Pediatr1981; 99: 975–9.
6.
KaplanSLMasonEOKvernlandSJLoiselleEMFeiginRD. Moxalactam therapy of non-central nervous system infections in children. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago (abstract 320).
7.
KeyserlingHFeldmanWEMoffittSManningNHollinsM. Clinical and pharmacological evaluation of moxalactam in pediatric patients. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, November, 1981, Chicago (abstract 321).
8.
YogevRSchreiberMGardnerSShulmanST. Moxalactam in pediatric infections. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. November, 1981, Chicago (abstract 322).
